Halozyme to Report Second Quarter 2025 Financial and Operating Results
Halozyme Therapeutics (NASDAQ: HALO) has scheduled the release of its second quarter 2025 financial and operating results for Tuesday, August 5, 2025, after market close. The company will host a conference call the same day at 1:30 p.m. PT/4:30 p.m. ET to discuss the results.
Investors can access the conference call through pre-registration and join the live webcast through Halozyme's investor relations website. A replay will also be available on the corporate website.
Halozyme Therapeutics (NASDAQ: HALO) ha programmato la pubblicazione dei suoi risultati finanziari e operativi del secondo trimestre 2025 per martedì 5 agosto 2025, dopo la chiusura dei mercati. La società terrà una conference call lo stesso giorno alle 13:30 PT/16:30 ET per discutere i risultati.
Gli investitori possono accedere alla conference call tramite pre-registrazione e partecipare alla diretta streaming attraverso il sito web delle relazioni con gli investitori di Halozyme. Una registrazione sarà inoltre disponibile sul sito aziendale.
Halozyme Therapeutics (NASDAQ: HALO) ha programado la publicación de sus resultados financieros y operativos del segundo trimestre de 2025 para el martes 5 de agosto de 2025, después del cierre del mercado. La empresa realizará una llamada conferencia el mismo día a las 1:30 p.m. PT/4:30 p.m. ET para analizar los resultados.
Los inversores pueden acceder a la llamada conferencia mediante preinscripción y unirse a la transmisión en vivo a través del sitio web de relaciones con inversores de Halozyme. También estará disponible una repetición en el sitio corporativo.
Halozyme Therapeutics (NASDAQ: HALO)는 2025년 8월 5일 화요일, 장 마감 후에 2025년 2분기 재무 및 운영 실적을 발표할 예정입니다. 회사는 같은 날 오후 1시 30분 PT / 오후 4시 30분 ET에 실적에 대해 논의하는 컨퍼런스 콜을 개최합니다.
투자자들은 사전 등록을 통해 컨퍼런스 콜에 접속할 수 있으며, Halozyme 투자자 관계 웹사이트를 통해 라이브 웹캐스트에 참여할 수 있습니다. 녹화본도 회사 웹사이트에서 제공될 예정입니다.
Halozyme Therapeutics (NASDAQ : HALO) a prévu de publier ses résultats financiers et opérationnels du deuxième trimestre 2025 le mardi 5 août 2025, après la clôture du marché. La société organisera une conférence téléphonique le même jour à 13h30 PT / 16h30 ET pour discuter des résultats.
Les investisseurs peuvent accéder à la conférence téléphonique en s'inscrivant à l'avance et rejoindre la diffusion en direct via le site web des relations investisseurs de Halozyme. Une rediffusion sera également disponible sur le site corporate.
Halozyme Therapeutics (NASDAQ: HALO) hat die Veröffentlichung seiner Finanz- und Betriebsergebnisse für das zweite Quartal 2025 für Dienstag, den 5. August 2025, nach Börsenschluss geplant. Das Unternehmen wird am selben Tag um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen.
Investoren können über eine Voranmeldung an der Telefonkonferenz teilnehmen und den Live-Webcast über die Investor-Relations-Website von Halozyme verfolgen. Eine Aufzeichnung wird ebenfalls auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
Halozyme will host a conference call on Tuesday, August 5, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link https://registrations.events/direct/Q4I78137779.
A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com
Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-second-quarter-2025-financial-and-operating-results-302510433.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When will Halozyme (NASDAQ:HALO) report Q2 2025 earnings?
What time is Halozyme's Q2 2025 earnings conference call?
How can investors access Halozyme's Q2 2025 earnings call?
Will there be a replay available of Halozyme's Q2 2025 earnings call?
